Unleash’s lead product, UIO-623, is a systemically delivered oncolytic virus.
UIO-623’s viral replication is triggered by a triple hybrid promoter that combines the stroma-associated SPARC gene promoter and motifs responsive to tumor microenvironment conditions such as inflammation and hypoxia.